...
首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin.
【24h】

Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin.

机译:血管内皮生长因子(VEGF),前列腺素E2(PGE2)和活性肾素在肾上腺素的高血压中。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

There are limited data regarding the role of vascular endothelial growth factor (VEGF) in arterial hypertension. The aim of the present study was to determine some markers of vascular function, including VEGF, active renin and prostaglandin E2 (PGE2) in patients with endocrine hypertension. The study comprised: 30 patients with primary aldosteronism; 32 patients with active Cushing's syndrome; 19 patients with pheochromocytoma; 22 patients with essential hypertension and 24 healthy volunteers. VEGF was significantly elevated in all groups of patients as compared to the controls. VEGF levels in patients with Cushing's syndrome were significantly higher than those in patients with essential hypertension and primary aldosteronism. We did not find significant differences in VEGF levels between patients with Conn adenomas and idiopathic aldosteronism as well as between patients with Cushing's disease and Cushing's syndrome. PGE2 levels were not significantly different among the groups. Active renin was significantly the lowest in patients with primary aldosteronism and significantly the highest in those with pheochromocytoma compared to controls. The level of active renin in patients with primary aldosteronism was significantly lower than in patients with Cushing's syndrome and pheochromocytoma. In conclusion, VEGF levels were significantly elevated in patients with endocrine hypertension due to glucocorticoid, mineralocorticoid and/or catecholamine excess. The highest VEGF levels were detected in patients with Cushing's syndrome. The latter is associated with accelerated development of atherosclerosis and increased cardiovascular risk. VEGF might contribute to the cardiovascular risk in this disease. This effect was not likely to be PGE2 mediated.
机译:关于血管内皮生长因子(VEGF)在动脉高血压中的作用存在有限的数据。本研究的目的是确定内分泌高血压患者的VEGF,活性肾素和前列腺素E2(PGE2)的一些标志物。该研究组成:30名患有原发性族长主义症的患者; 32例活性缓冲综合征; 19例嗜铬细胞瘤患者; 22名患有高血压和24名健康志愿者的患者。与对照组相比,所有患者的VEGF在患者中显着升高。库欣综合征患者的VEGF水平明显高于原发性高血压和原发性醛固酮患者的患者。我们没有在Conn腺瘤和特发性醛固酮中的患者之间存在显着差异,以及在患有库什氏病和缓冲综合征之间的患者之间。群体在群体中没有显着差异。活跃的肾素在原发性醛雌激素的患者中显着最低,与对照相比,嗜铬细胞瘤的患者中最高。原发性醛固酮患者中活性肾素的水平明显低于缓冲综合征和嗜铬细胞瘤的患者。总之,由于糖皮质激素,矿物质激素和/或儿茶酚含量过量,内分泌高血压患者的VEGF水平显着升高。在缓冲综合征患者中检测到最高VEGF水平。后者与动脉粥样硬化的加速发展和心血管风险增加有关。 VEGF可能有助于这种疾病的心血管风险。这种效果不太可能是PGE2介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号